Adanma Ayanambakkam

Dr. Adanma Ayanambakkam


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2026 in European Urology Oncology
Verified
Journal Article
Open access
KRKevin R. Reyes
Kevin R. Reyes
RZRyan Zhu
Ryan Zhu
CHCameron Herberts
Cameron Herberts
PDPunashi Dutta
Punashi Dutta
AWAshley Wray
Ashley Wray
VKVadim S Koshkin
Vadim S Koshkin
Enfortumab vedotin (EV) plus pembrolizumab (P) is the preferred first-line therapy for locally advanced or metastatic urothelial carcinoma (la/mUC); however, responses remain heterogeneous, and biomarkers are limited. We evaluated longitudinal tumor-informed circulating tumor DNA (ctDNA) as a potential real-time prognostic biomarker in patients with la/mUC initiating EV with or without P (EV±P). This is an exploratory, real-world retrospective, multicenter analysis of patients with la/mUC who received personalized, tumor-informed ctDNA testing (Signatera, Natera, Inc.) coinciding with their EV±P treatment. Across 545 plasma samples from 110 patients (median follow-up 60.6 weeks (wk)), baseline ctDNA was detected in 93.6% and declined or cleared within 12 wk in 75.8% and 33.9%, respectively. In all evaluated time intervals, ctDNA positivity on-treatment was consistently associated with inferior progression-free survival (PFS) and overall survival (OS) compared to ctDNA negativity (PFS 4-12 wk: hazard ratio [HR] = 10.08; p < 0.001; 12-24 wk: HR = 11.84; p < 0.001; >24 wk: HR = 6.77; p < 0.001; OS 4-12 wk: HR = 6.53; p = 0.013; 12-24 wk: HR = 7.22; p = 0.0083; >24 wk: HR = 3.81; p = 0.025) and remained independently prognostic on multivariable analyses. ctDNA dynamics relative to baseline were similarly prognostic: persistent positivity within 12 wk was associated with shorter PFS (HR = 8.96; p = 0.0004) and OS (HR = 4.58; p = 0.016), whereas early ctDNA clearance was enriched among radiographic responders (p < 0.001). Limitations include the retrospective design, non-standardized ctDNA sample collection, and heterogeneity in evaluation and treatment approaches. Personalized, tumor-informed ctDNA testing can indicate response to EV±P and is prognostic of survival benefit in patients with la/mUC receiving EV±P.

20 May 2026 in Cancers
Verified
Journal Article
Open access
PDF file
APAmulya Prakash
Amulya Prakash
ACAdriani Samuel Cherico
Adriani Samuel Cherico
AAAdanma Ayanambakkam
Adanma Ayanambakkam
HPHyma Polimera
Hyma Polimera
Upper tract urothelial carcinoma (UTUC) presents distinct diagnostic and therapeutic challenges because of its rarity, anatomic constraints, frequent understaging at biopsy, and risk of systemic recurrence after radical nephroureterectomy. Current perioperative management is driven primarily by clinicopathologic risk factors, which may be insufficient to identify occult molecular residual disease (MRD) or to determine which patients are most likely to benefit from systemic therapy. This narrative review summarizes available evidence on circulating tumor DNA (ctDNA) in UTUC and related urothelial carcinoma settings, classifies the level of evidence supporting each application, and proposes a research framework for prospective evaluation. The strongest UTUC-specific evidence supports ctDNA as a prognostic biomarker associated with recurrence risk, whereas predictive validity for selecting chemotherapy, immune checkpoint inhibitors, antibody-drug conjugates, targeted therapy, or surveillance intensity remains unproven. Evidence from muscle-invasive bladder cancer, including ctDNA-correlative and ctDNA-guided perioperative trials, provides biologic rationale but should not be directly translated into routine UTUC care without disease-specific validation. We outline key implementation questions, including target population, assay selection, timing, false-positive and false-negative results, lead-time bias, and integration of plasma ctDNA with utDNA. Prospective UTUC-specific trials are needed to determine whether ctDNA-guided perioperative strategies improve survival, reduce unnecessary toxicity, and are cost-effective.

19 May 2026 in Cancers
Verified
Journal Article
Open access
PDF file
EAEvan Adler
Evan Adler
AMAnwaruddin Mohammad
Anwaruddin Mohammad
PKPankaj Kumar
Pankaj Kumar
RRRobert Rounbehler
Robert Rounbehler
MCMichelle L Churchman
Michelle L Churchman
PVPaul Vincent Viscuse
Paul Vincent Viscuse
Background: Prostate cancer is a heterogeneous disease with variable clinical outcomes. If localized, the patient may be cured. However, prostate cancer is lethal if recurrence/progression to metastatic castrate resistant disease occurs. Thus, there is an unmet need to further understand the molecular underpinnings of this progression. Epidemiologic studies show that increased risk of developing and dying from prostate cancer has been associated with elevated serum IGF-1 levels, hyperinsulinemia and metabolic syndrome. Alterations in insulin pathway genes, such as PTEN, FOXO, and PIK3CA, are mutated in up to 32%, 15%, and 11% of localized prostate tumors, respectively. We aimed to further characterize expression of insulin pathway genes in localized prostate cancers in an effort to (1) provide insights into potential mechanisms of progression to metastatic disease and (2) try to further enrich for those prostate tumors that portend worse survival outcomes. Methods: Using the multi-institutional Oncology Research Information Exchange Network (ORIEN) database, gene expression data was analyzed from localized prostate cancer tumors. The raw counts were first normalized, and 176 genes related to the insulin receptor and its downstream pathways were then subset and used for clustering using the non-negative matrix factorization (NMF). The NMF cluster analysis was performed in an attempt to separate gene expression into two groups. Gene Set Enrichment Analysis (GSEA) was then performed between the two groups that had been separated by cluster analysis to determine homology between other GSEA sets. Kaplan–Meier curves were used to assess median overall survival. Cox analysis was performed to generate the adjusted KM curve. Mediation analysis was conducted to determine the relationship between cluster status, TN stage, and survival. Results: Cluster analysis revealed two distinct groups of insulin gene expression, cluster 1 (n = 96) and cluster 2 (n = 337). Compared with cluster 2, cluster 1 consisted of decreased expression of PTEN (p < 0.001) and PIK3R1 (p < 0.001), along with increases in the expression of AKT1 (p < 0.001), IRS1/2 (p < 0.001), FASN (p < 0.001), IGFBP2 (p < 0.001), and MTOR (p < 0.001). GSEA analysis revealed changes in lipid metabolism and WNT secretion pathways in cluster 1. Cluster 2 GSEA showed pathway changes related to DNA damage repair and testosterone. Patient characteristics between clusters differed significantly in the T and N stages of tumor but not in other ways. In unadjusted analysis, median overall survival was estimated at 117 months and 232 months for cluster 1 and cluster 2, respectively (p < 0.05). The proportion of patients who went on to develop metastases (p < 0.05) or need chemotherapy (p < 0.05) was increased in cluster 1 compared to cluster 2. Repeat survival analysis adjusted for confounders (T stage, N stage, age at diagnosis, pathologic grade) showed no difference in survival between clusters. Mediation analysis showed that the contribution of cluster status to survival was independent of T or N stage. Conclusions: A subset of localized prostate cancer patients demonstrated linked insulin pathway changes that are consistent with prior studies describing a pattern of insulin dysregulation. Though the group characterized by insulin dysregulation initially showed worse survival outcomes, this difference disappeared when controlling for confounders. Though baseline differences in tumor stage seemed to most readily explain the difference in survival between clusters, mediation analysis showed that the effect of cluster status on survival was independent of tumor stage. This suggests that other confounders, such as pathologic grade or baseline age, may explain the survival difference.